Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.
Silvestris, N., Maiello, E., De Vita, F., Cinieri, S., Santini, D., Russo, A., et al. (2010). Update on capecitabine alone and in combination regimens in colorectal cancer patients. CANCER TREATMENT REVIEWS, 36(SUPPL. 3), S46-S55 [10.1016/S0305-7372(10)70020-7].
Update on capecitabine alone and in combination regimens in colorectal cancer patients
Santini, D.;Russo, A.;
2010-01-01
Abstract
Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Update on capecitabine alone and in combination regimens in.pdf
accesso aperto
Dimensione
242.14 kB
Formato
Adobe PDF
|
242.14 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
